Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
Objectives
- To characterize infectious exacerbations of chronic obstructive pulmonary disease (COPD)
- To identify biological markers of infection in COPD
- To rationalize the use of antibiotics in exacerbations of COPD
Projects in Progress
- Study of the value of procalcitonin (PCT) in exacerbations of COPD requiring hospitalization
- Multicenter study of the prevalence of infections due to Aspergillus species in exacerbations of COPD
- Multicenter study on optimizing the diagnosis of exacerbations in COPD: AUDIEPOC
- Utility of Antibiotic Treatment in Exacerbations of COPD Without Sputum Purulence: a Randomized, Double-Blind Controlled Clinical Trial on Efficacy and Safety.
Milestones Achieved
- It has been reported that bacterial infection causes 50% of exacerbations of COPD
- Bacterial colonization in COPD correlates significantly with the cytokine-associated inflammatory response in bronchoalveolar lavage
- Sputum purulence as an exacerbation criterion correlates with the existence of bacterial infection in exacerbations of COPD
Future Challenges
- Identification of biological markers for rapid detection of infectious exacerbations of COPD in severe and outpatient cases
- Study of the relevance of colonization of the airways by Aspergillus species in patients with severe COPD
- Search for an effective strategy to rationalize the widespread use of antibiotics in COPD
Publications
Geographic differences in clinical characteristics and management of COPD: the EPOCA study
Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, Joan B Soriano, Alejandra Ramirez-Venegas, Fanny WS Ko, Byron Canelos-Estrella, Eduardo Giugno, Miguel Bergna, Ivan Chérrez, Antonio Anzueto.
International Journal of COPD. 2008:3(4) 1–12.
Lines list
- Alfa 1 antitripsina
- Animal Model
- ARDS-ALI
- Community-Acquired Pneumonia (CAP)
- Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Lung Cancer
- Networks, European Projects and Collaborations
- Noninvasive Ventilation (NIV)
- Pulmonary complications in immunocompromised (IC) patients
- Ventilator-Associated Pneumonia (VAP)



